Form 4: Krystal Biotech Executive Suma Krishnan Reports Stock Transactions

Suma Krishnan, President of R&D at Krystal Biotech, reports multiple transactions involving common stock and derivative securities, including acquisitions, disposals, and vesting of performance stock units and restricted stock units.

Summary

• Suma Krishnan, President of R&D at Krystal Biotech, filed a Form 4 detailing changes in beneficial ownership.
• The reported transactions include the disposal of shares to cover tax withholdings upon the vesting of restricted stock and performance stock units.
• Krishnan also reported the acquisition of shares through the vesting of performance stock units.
• Additionally, Krishnan's spouse, Krish S. Krishnan, also had transactions involving performance stock units and restricted stock units, which are reported on this form.
• A new stock option for 25,000 shares was granted to Suma Krishnan, vesting in four equal annual installments beginning February 28, 2026.
• 16,000 restricted stock units were also granted to Suma Krishnan, vesting in four equal annual installments beginning February 28, 2026.
• After these transactions, Suma Krishnan directly owns 1,488,711 shares of common stock and indirectly owns 1,562,777 shares through her spouse, SMK Trust, and Krishnan Family Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reflects routine transactions related to equity compensation. The vesting of PSUs suggests the achievement of performance goals, which is mildly positive.

Positives

• The vesting of performance stock units indicates that performance criteria set by the company's Compensation Committee were met.
• The granting of new stock options and restricted stock units to Suma Krishnan suggests continued confidence in her role and contribution to the company.
• The increase in indirect ownership through spouse and trusts indicates a strong alignment of interests with the company's success.

Future Outlook

The document outlines future vesting dates for stock options and restricted stock units, indicating continued equity-based compensation for the reporting person.

Industry Context

Form 4 filings are standard practice for publicly traded companies and provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotechnology industry to attract and retain talent.
• Vesting schedules for stock options and restricted stock units are typically structured over several years to incentivize long-term commitment.
• The size and structure of the equity grants are generally aligned with industry benchmarks for similar roles and company size.

Stakeholder Impact

• Shareholders may view the vesting of performance stock units as a positive sign, indicating that the company is achieving its performance targets.
• Employees may be motivated by the equity compensation structure, aligning their interests with the company's long-term success.

Key Dates